A Case of High Grade Advanced Neuroendocrine Cancer of the Bladder Treated with Bevacizumab, Cisplatin, Etoposide and Cyclophosphamide-Based Chemotherapy

Sroussi M, Fournier L, Blons H and Oudard S

Department of Oncology, European Georges Pompidou Hospital, René Descartes University, France
Department of Radiology, European Georges Pompidou Hospital, René Descartes University, France
Department of Biochemistry, European Georges Pompidou Hospital, René Descartes University, France

^*Correspondance to: St�phane Oudard 

 PDF  Full Text Case Report | Open Access

Abstract:

Neuroendocrine bladder cancer accounts for <1% of all bladder cancers. There is no standard treatment for neuroendocrine bladder cancer; instead therapy is mainly based on agents used in small cell lung cancer. The case report details a patient with neuroendocrine bladder cancer who had disease progression after conventional chemotherapy based on etoposide and cisplatin. During second-line chemotherapy with etoposide, cisplatin and ifosfamide the patient experienced a high-grade neurological adverse event, without any decrease in tumor burden. Third-line chemotherapy with cisplatin, cyclophosphamide, etoposide and bevacizumab was associated with an almost complete response but the patient died of hematological toxicity. The good response to the combination of cisplatin, cyclophosphamide, etoposide and bevacizumab suggests that antiangiogenic therapies may be a treatment option for neuroendocrine bladder cancer that deserved further study.

Keywords:

Small cell bladder cancer; Bevacizumab; Cisplatin; Etoposide; Cyclophosphamide; Hematotoxicity

Cite the Article:

Sroussi M, Fournier L, Blons H, Oudard S. A Case of High Grade Advanced Neuroendocrine Cancer of the Bladder Treated with Bevacizumab, Cisplatin, Etoposide and CyclophosphamideBased Chemotherapy. Clin Oncol. 2016; 1: 1050.